Invesco Ltd. Purchases 65,655 Shares of Nurix Therapeutics, Inc. $NRIX

Invesco Ltd. raised its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 126.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 117,635 shares of the company's stock after buying an additional 65,655 shares during the period. Invesco Ltd. owned about 0.15% of Nurix Therapeutics worth $1,398,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. ARK Investment Management LLC increased its holdings in shares of Nurix Therapeutics by 4.0% in the 1st quarter. ARK Investment Management LLC now owns 1,590,910 shares of the company's stock worth $18,900,000 after buying an additional 60,617 shares during the last quarter. Hussman Strategic Advisors Inc. bought a new position in shares of Nurix Therapeutics in the 1st quarter worth $499,000. Vanguard Group Inc. increased its holdings in shares of Nurix Therapeutics by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 4,415,122 shares of the company's stock worth $52,452,000 after buying an additional 69,856 shares during the last quarter. Ensign Peak Advisors Inc lifted its holdings in shares of Nurix Therapeutics by 108.2% in the 4th quarter. Ensign Peak Advisors Inc now owns 374,673 shares of the company's stock worth $7,059,000 after acquiring an additional 194,673 shares during the last quarter. Finally, Velan Capital Investment Management LP bought a new stake in shares of Nurix Therapeutics in the 4th quarter worth approximately $1,844,000.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 5,402 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $11.03, for a total transaction of $59,584.06. Following the completion of the transaction, the chief financial officer owned 35,512 shares in the company, valued at $391,697.36. This represents a 13.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 4,308 shares of the company's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the transaction, the insider owned 69,023 shares of the company's stock, valued at approximately $828,966.23. This represents a 5.87% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,014 shares of company stock valued at $163,014. 7.40% of the stock is owned by corporate insiders.

Nurix Therapeutics Stock Up 8.7%

Shares of Nurix Therapeutics stock traded up $0.79 on Friday, hitting $9.91. The stock had a trading volume of 831,891 shares, compared to its average volume of 699,832. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56. The stock has a market cap of $757.62 million, a price-to-earnings ratio of -3.80 and a beta of 2.10. The stock's 50-day simple moving average is $10.95 and its two-hundred day simple moving average is $11.49.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. The firm had revenue of $44.06 million for the quarter, compared to analysts' expectations of $16.26 million. As a group, equities analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NRIX shares. Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Stephens reissued an "overweight" rating and issued a $30.00 price target on shares of Nurix Therapeutics in a research note on Thursday, July 10th. Baird R W raised shares of Nurix Therapeutics to a "strong-buy" rating in a research note on Tuesday, August 26th. HC Wainwright lowered their price target on shares of Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, July 14th. Finally, UBS Group lowered their price target on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Nurix Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $29.07.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.